Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating

Julian Harrison, an analyst from BTIG, maintained the Buy rating on Viridian Therapeutics (VRDN – Research Report). The associated price target is $61.00.

Julian Harrison has given his Buy rating due to a combination of factors related to Viridian Therapeutics’ promising developments in treating Thyroid Eye Disease (TED). The company’s lead candidate, veligrotug, has demonstrated durable efficacy and consistent safety over a 52-week period, with a significant portion of patients maintaining their response long after treatment. This positions veligrotug favorably against existing treatments like Tepezza, particularly due to its less burdensome infusion regimen and shorter infusion time.
Additionally, the positive long-term data from veligrotug is expected to benefit Viridian’s subcutaneous autoinjector program, VRDN-003, which shares the same binding domain. The potential for a self-administered treatment option is likely to be attractive to payors, given the reduced costs associated with avoiding IV infusions. With no other late-stage development efforts for a similar subcutaneous option, Viridian is well-positioned to capture a significant portion of the TED market. The anticipated BLA submission in the second half of 2025 and potential approval and launch in 2026 further support the Buy rating.

In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $41.00 price target.

VRDN’s price has also changed moderately for the past six months – from $19.790 to $13.820, which is a -30.17% drop .